Skip to main content

Table 4 Quality-adjusted progression-free and Overall Survival

From: Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone

Parameter

CMFP (n=194)

Mitoxantrone (n=197)

Difference

95% CI

P*

Mean progression-free months†

7.975

6.666

1.309

0.047 to 2.648

0.05

Mean utility from randomisation to 1st disease progression

0.904

0.895

0.009

−0.006 to 0.022

0.16

Quality-adjusted progression-free survival

7.208

5.965

1.243

0.119 to 2.487

0.04

Mean overall survival months‡

13.330

12.813

0.517

−1.266 to 2.560

0.62

Mean utility from randomisation to death

0.888

0.883

0.005

−0.007 to 0.014

0.35

Quality-adjusted overall survival

11.832

11.315

0.517

−1.120 to 2.296

0.57

  1. * The 95% confidence interval and P value were obtained by bootstrap sampling with 1000 replications.
  2. † Mean progression-free survival was calculated as the area under the curve for the time from randomization to first disease progression, truncated at 24 months.
  3. ‡ Mean overall survival was calculated as the area under the curve for the time from randomization to death, truncated at 30 months.
  4. CMFP, combination therapy with cyclophosphamide, methotrexate, 5-fluorouracil and prednisone.